三阴性乳腺癌
乳腺癌
医学
肿瘤科
内科学
免疫系统
癌症
免疫学
作者
Sylvie Rusakiewicz,Svitlana Tyekucheva,S. Tissot-Renaud,Kariman Chaba,Martina Imbimbo,Fabio Benedetti,Roswitha Kammler,J. Hornfeld,Elisabetta Munzone,Luca Gianni,Beat Thürlimann,István Láng,Giancarlo Pruneri,KP Gray,Meredith M. Regan,Sherene Loi,Marco Colleoni,Giulia Viale,Lana E. Kandalaft,George Coukos,Giuseppe Curigliano
标识
DOI:10.1016/j.ejca.2024.113535
摘要
Background Triple-negative breast cancer (TNBC) is the most aggressive breast cancer (BC) subtype, with dismal prognosis and limited option in advanced settings, yet stromal tumor infiltrating lymphocytes (sTILs) in this subtype has a predictive role. Patients and methods: The International Breast Cancer Study Group (IBCSG) Trial 22-00 is a randomized phase III clinical trial testing the efficacy of low-dose metronomic oral Cyclophosphamide-Methotrexate (CM) maintenance following standard adjuvant chemotherapy treatment for early-stage hormone receptor-negative breast cancer patients. A case-cohort sampling was used. We characterized immune cells infiltrates in patients with TNBC by 6 plex immunofluorescence (IF) staining for CD4, FOXP3, CD3, cytokeratine and CD8 Results We confirmed that high immune CD3+ T cells as well as stromal and intra-epithelial Tregs (CD4+Foxp3+ T cells) infiltrates were associated with a better Distant Recurrence-Free Interval (DRFI), especially in LN+ patient, regardless of the treatment. More importantly, we showed that the spatial distribution of immune cells at baseline is crucial, as CM maintenance was detrimental for T cells excluded LN+ TNBC patients. Conclusions immune spatial classification on immune cells infiltrates seems crucial and could help patients’ selection in clinical trial and greatly improve responses to specific therapies.
科研通智能强力驱动
Strongly Powered by AbleSci AI